| Hans-Günter Meyer-Thompson | Fachveröffentlichungen
An opioid-withholding human laboratory paradigm during opioid agonist treatment for opioid use disorder and chronic pain: Phase- and dose-dependent effects of cannabidiol.
An opioid-withholding human laboratory paradigm during opioid agonist treatment for opioid use disorder and chronic pain: Phase- and dose-dependent effects of cannabidiol.
P A Costa G, Sofuoglu M, Compton P, Ranganathan M, Pittman B, De Aquino JP.
Neuropsychopharmacology. 2026 May 20:10.1038/s41386-026-02443-w. doi: 10.1038/s41386-026-02443-w. Epub ahead of print. PMID: 42162267; PMCID: PMC13213852.